Site of absorption of an oral formulation of semaglutide - ADA 2017
Absorption of oral peptide-based drug formulations is challenged by the fact that peptides are degraded in the stomach due to low pH and proteolytic enzymes, as well as by their limited permeability across the gastrointestinal epithelium.
A pharmacoscintigraphic study of the relationship between tablet erosion and pharmacokinetics of oral semaglutide - ADA 2017
When administered orally, peptide-based drugs are susceptible to degradation in the stomach due to exposure to low pH and proteolytic enzymes.
A randomised double-blind dose escalation study- ASCPT 2016
A randomised double-blind dose escalation study to evaluate the safety and dose response of subcutaneous administration of coversin in healthy subjects.
Clinical Pharmacokinetics and Pharmacodynamics of ME-401 - AACR 2016
Clinical Pharmacokinetics and Pharmacodynamics of ME-401, an Oral, Potent and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers
Rapid Formulation Development and Clinical Testing of Gastro-Retentive Controlled Release Technology to Enable Once-Daily Dosing
MK-X had demonstrated poor colonic absorption in dogs and conventional matrix based controlled release formulations failed to achieve adequate trough concentrations in a human pharmacokinetic (PK) study to support once daily dosing.